Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

@inproceedings{Ahmadzadehfar2015EarlySE,
  title={Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study},
  author={Hojjat Ahmadzadehfar and Kambiz Rahbar and Stefan Kuerpig and Martin Boegemann and Michael Claesener and Elisabeth Eppard and Florian G{\"a}rtner and Sebastian Rogenhofer and Michael Sch{\"a}fers and Markus Essler},
  booktitle={EJNMMI research},
  year={2015}
}
BACKGROUND Radioligand therapy (RLT) with (177)Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with Lu-PSMA in our departments. METHODS RLT was performed in ten hormone- and/or chemo-refractory patients with distant metastases and progressive disease (mean age 73.5 years). (68)Ga-PSMA HBED-CC PET/CT… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 65 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…